投融资数据库
免费查数据
注册送3天会员
首页>投融资
Indapta Therapeutics
未公开
Indapta Therapeutics Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors.In February 2021, Indapta Therapeutics Inc. appointed Lori Kunkel, M.D., as its Senior Clinical Advisor, Robert Sikorski, M.D., Ph.D., as its Founding Chief Medical Officer, and Jim Weiss as a member of its Board of Directors.Indapta Therapeutics Inc Headquartered in San Francisco
基本信息
-
公司全称Indapta Therapeutics Inc
-
类型同种异体细胞疗法开发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址5000 Montrose Blvd. HOUSTON TEXAS 77006; US; Telephone: +19172829768;
-
联系电话
-
邮箱info@indapta.com
-
成立时间2017-01-01
投融资
-
2024-12-17
-
2024-05-21
-
2022-02-10
相关投融资企业
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
E~PreIPO
Arthrosi Therapeutics LLC focuses on the treatment of uric acid levels and reduce joint damage for people living with gout.In July 2023, Arthrosi Therapeutics secured of $75 million in Series D financing
收并购
Kronos Bio, Inc.于2017年6月2日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，致力于发现和开发新的癌症疗法，旨在通过针对失调转录的精确药物策略来改变患者的预后。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息